AlphaMadera

Kenvue Inc. (KVUE)

Stock NYSE

$19.31

-0.25 (-1.28%)

Delayed quote.

Price history

Daily close
KVUE daily closing price, Nov 10, 2025 to Oct 30, 2026 Closed at $16.77 on Nov 10, 2025 and $19.31 on Oct 30, 2026, a change of +15.15%. Range $16.06 to $19.88.
Daily closes, Nov 10, 2025 to Oct 30, 2026 (245 trading days).
Start
$16.77
Latest close
$19.31
Period change
+15.15%
Period low
$16.06
Period high
$19.88

Key metrics

Market cap
$37.09B
Volume
66.38M
Average volume
21.80M
52-week range
$15.94 – $20.13
Beta
0.45
Last dividend
$0.83
EPS (TTM)
$0.88
P/E ratio
21.94
Revenue (TTM)
$15.53B
Net income (TTM)
$1.69B
Total assets
$26.67B
Total debt
$8.34B
Cash and equivalents
$1.04B

Key financials (trailing twelve months).

Company profile

Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health. Within the Self Care unit, it offers a diverse range of products for common conditions like coughs, colds, and allergies, in addition to pain relief, digestive health, and smoking cessation aids, featuring prominent brands such as Tylenol, Nicorette, and Zyrtec. The Skin Health and Beauty segment delivers various solutions for facial, body, hair, and sun protection, recognized under popular labels including Neutrogena, Aveeno, and OGX. Moreover, the Essential Health category provides oral hygiene, infant care, feminine wellness, and wound treatment products, marketed through esteemed brands like Listerine, Johnson's, Band-Aid, and Stayfree. Established in 2022, Kenvue Inc. maintains its corporate headquarters in Skillman, New Jersey, and operates as a subsidiary of Johnson & Johnson.

Sector
Consumer Defensive
Industry
Household & Personal Products
Exchange
NYSE
CEO
Kirk L. Perry
Employees
21,890
Headquarters
Summit, NJ, US
IPO date
2023-05-04
Website
https://www.kenvue.com

Financial statements

Annual, last 3 fiscal years. Most recent period first. Reported in USD.

Income statement
MetricFY2025Dec 28, 2025FY2024Dec 29, 2024FY2023Dec 31, 2023
Revenue$15.12B$15.46B$15.44B
Gross profit$8.79B$8.96B$8.64B
Operating income$2.70B$1.84B$2.51B
EBITDA$2.94B$2.47B$3.17B
Net income$1.47B$1.03B$1.66B
Diluted EPS$0.76$0.54$0.87
Balance sheet
MetricFY2025Dec 28, 2025FY2024Dec 29, 2024FY2023Dec 31, 2023
Cash and equivalents$1.06B$1.07B$1.38B
Total assets$27.08B$25.60B$27.85B
Total liabilities$16.31B$15.93B$16.64B
Total debt$8.52B$8.72B$8.43B
Shareholders’ equity$10.77B$9.67B$11.21B
Cash flow statement
MetricFY2025Dec 28, 2025FY2024Dec 29, 2024FY2023Dec 31, 2023
Operating cash flow$2.20B$1.77B$3.17B
Capital expenditure-$475.00M-$434.00M-$469.00M
Free cash flow$1.72B$1.33B$2.70B

Quarterly, last 6 quarters. Most recent period first. Reported in USD.

Income statement
MetricQ3 2026Sep 27, 2026Q2 2026Jun 28, 2026Q1 2026Mar 29, 2026Q4 2025Dec 28, 2025Q3 2025Sep 28, 2025Q2 2025Jun 29, 2025
Revenue$3.89B$3.96B$3.91B$3.78B$3.76B$3.84B
Gross profit$2.31B$2.30B$2.30B$2.14B$2.23B$2.26B
Operating income$706.00M$699.00M$855.00M$825.00M$629.00M$692.00M
EBITDA$856.00M$833.00M$910.00M$663.00M$760.00M$837.00M
Net income$430.00M$456.00M$474.00M$330.00M$398.00M$420.00M
Diluted EPS$0.22$0.24$0.25$0.17$0.21$0.22
Balance sheet
MetricQ3 2026Sep 27, 2026Q2 2026Jun 28, 2026Q1 2026Mar 29, 2026Q4 2025Dec 28, 2025Q3 2025Sep 28, 2025Q2 2025Jun 29, 2025
Cash and equivalents$1.04B$1.11B$1.07B$1.06B$1.14B$1.07B
Total assets$26.67B$26.73B$26.85B$27.08B$27.25B$27.13B
Total liabilities$16.51B$16.18B$16.25B$16.31B$16.61B$16.40B
Total debt$8.34B$8.48B$8.66B$8.52B$9.11B$8.74B
Shareholders’ equity$10.16B$10.55B$10.61B$10.77B$10.63B$10.73B
Cash flow statement
MetricQ3 2026Sep 27, 2026Q2 2026Jun 28, 2026Q1 2026Mar 29, 2026Q4 2025Dec 28, 2025Q3 2025Sep 28, 2025Q2 2025Jun 29, 2025
Operating cash flow$700.00M$688.00M$489.00M$854.00M$294.00M$621.00M
Capital expenditure-$80.00M$138.80M-$139.00M-$110.00M-$98.00M-$88.00M
Free cash flow$620.00M$826.80M$350.00M$744.00M$196.00M$533.00M